

Classification of Focus
● Active foci


I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
Number of active foci	6		Plasmodium species: <i>P. falciparum</i> (0%), <i>P. vivax</i> (100%)
Number of people living within active foci	9,590	0	Major anopheles species: <i>An. albimanus</i> , <i>An. pseudopunctipennis</i>
Malaria-free (0 cases)	6,340,000	100	Reported confirmed cases (health facility): 13
Total	6,345,000		Confirmed cases at community level: 0
			Reported deaths: 0


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	No	-	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2013	First-line treatment of <i>P. falciparum</i>	CQ+PQ(1d)	-					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	AL	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	2012					
Larval control	Use of larval control recommended	Yes	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2010	Type of RDT used		-					
	Malaria diagnosis is free of charge in the public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)							
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-								
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-								
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-								
	G6PD test is a requirement before treatment with primaquine	No	-								
	Directly observed treatment with primaquine is undertaken	Yes	-								
	System for monitoring adverse reactions to antimalarials exists	Yes	-								
Surveillance	ACD for case investigation (reactive)	Yes	-	Insecticide resistance tests (mosquito mortality, %)							
	ACD of febrile cases at community level (pro-active)	Yes	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	Mass screening is undertaken	Yes	2015								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	Yes	-								
Case reporting from private sector is mandatory	Yes	-									





III. Financing





Government expenditure by intervention in 2016



IV. Coverage



V. Impact



Notes:
Reported confirmed cases and reported deaths are indigenous only